about
Small interfering RNAs containing full 2'-O-methylribonucleotide-modified sense strands display Argonaute2/eIF2C2-dependent activity.Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticleInsights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imagingGeneration of Aptamers with an Expanded Chemical RepertoiresiRNA Versus miRNA as Therapeutics for Gene SilencingsiRNA Delivery from an Injectable Scaffold for Wound TherapyUnexpected origins of the enhanced pairing affinity of 2'-fluoro-modified RNATechnologies for controlled, local delivery of siRNARNA interference and potential therapeutic applications of short interfering RNAsCD40 gene silencing reduces the progression of experimental lupus nephritis modulating local milieu and systemic mechanismsInhibition of cell proliferation by an anti-EGFR aptamerRecent advances in hepatocellular carcinoma therapy.Sniffing for gene-silencing efficiency of siRNAs in HeLa cells in comparison with that in HEK293T cells: correlation between knockdown efficiency and sustainability of sirnas revealed by FRET-based probingSelf-assembled Micelle Interfering RNA for Effective and Safe Targeting of Dysregulated Genes in Pulmonary FibrosisChemical modification: the key to clinical application of RNA interference?Both strands of siRNA have potential to guide posttranscriptional gene silencing in mammalian cells.Phenotypic screen of early-developing larvae of the blood fluke, schistosoma mansoni, using RNA interference.Applications of mass spectrometry to the study of siRNA.High-density lipoproteins for the systemic delivery of short interfering RNA.Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo.Probing the inherent stability of siRNA immobilized on nanoparticle constructs.siRNA-like double-stranded RNAs are specifically protected against degradation in human cell extract.Effect of chemical modifications on modulation of gene expression by duplex antigene RNAs that are complementary to non-coding transcripts at gene promoters.Improved siRNA/shRNA functionality by mismatched duplex.Efficient and targeted delivery of siRNA in vivo.Transient expression of proteins by hydrodynamic gene delivery in mice.Optimizations of siRNA design for the activation of gene transcription by targeting the TATA-box motif.Unlocking the potential of the human genome with RNA interference.Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs.siRNAmod: A database of experimentally validated chemically modified siRNAsFabrication of stable and RNase-resistant RNA nanoparticles active in gearing the nanomotors for viral DNA packaging.Enzymatic synthesis of modified oligonucleotides by PEAR using Phusion and KOD DNA polymerases.Controlling activation of the RNA-dependent protein kinase by siRNAs using site-specific chemical modificationDevelopment of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy.Non-condensing polymeric nanoparticles for targeted gene and siRNA deliveryPossibilities for RNA interference in developing hepatitis C virus therapeutics.Cell-penetrating and neurotargeting dendritic siRNA nanostructures.Hydrophobization and bioconjugation for enhanced siRNA delivery and targetingFunctionally enhanced siRNA targeting TNFα attenuates DSS-induced colitis and TLR-mediated immunostimulation in mice.Low molecular weight chitosan nanoparticulate system at low N:P ratio for nontoxic polynucleotide delivery.
P2860
Q24537508-45254459-1DCE-4D61-A8AC-9C5D5198B962Q24560011-2B80D3F0-A9BF-4923-A458-8B76B6C33A3EQ25255924-5B623043-3505-4145-8D2A-9D3F4EDC1F05Q26782794-51643049-7309-46C5-9131-A39574028F52Q26786876-3E6A6492-E9BA-432D-BAB5-AA651EB4ED52Q27026234-D0D5BAD5-AFA5-4E20-9A21-33F885F523EDQ27666384-76AA8B3B-2362-4E52-9066-23962FF2C756Q28087657-A92654D9-7F6E-4D95-81BD-006F2C6B82D2Q28250480-1C453C7F-24F3-47E0-B01B-CFC3B295E280Q28533954-1633D2DE-946E-4510-9058-AA93715A50E1Q28743866-C6E32903-91C0-499B-80CB-5E5125F78453Q30236010-F1828B8F-90C0-4956-9E88-133426C833E9Q30538460-97254200-0D74-40B8-B94B-0B447F7C0133Q30734485-244F5799-5744-4BCB-9F11-154C8399F75DQ33308712-C74516E1-D75B-4910-825B-0B6573A8F164Q33436229-9B3DD250-5F68-4D0C-9FB4-CBEF56A7358FQ33492321-421CD85E-2EA2-438B-9F9A-D6F8487EF0A7Q33536680-1FE4D3D6-2A08-472C-9696-60E7F67600CCQ33786171-9CCFAEC2-298E-488B-81F1-0895A5BCDB3CQ33913718-AF538C3E-3C98-48D3-857E-4D67940FDC22Q33919726-5872D0AB-716D-4139-BAF0-E85F6E441A58Q33925270-B208E719-DF70-4B2F-B24C-EEEEEFE559F3Q34080079-A26378CD-F0DC-4B6A-9AFD-926BC7D17275Q34103204-1FA59C49-4C74-4371-A3D7-527753DBAAEDQ34149828-0615198B-2B68-4AE1-BF93-1F4F68A446ECQ34237207-1347A755-459B-48FB-98DF-A282C5BF3926Q34252830-A083C7BA-B0A9-4AC4-8359-05E47E9E437CQ34348958-4C9E6110-8A87-4A5E-A4C9-CFECB4F01EEDQ34436572-03E6D9A1-5CB7-41C8-B353-B06340E94604Q34511095-C90DA097-1F1F-4B4F-BFC0-6C31212D911CQ34520490-67165470-7DC8-469B-9B05-BDBF7772051EQ34976847-A6C33F4D-3829-4E82-A473-B70FB6BF794BQ35127967-837CA1A3-5C20-48BF-9654-A96D5DBDF59EQ35179033-F3C6745A-26EC-44AD-ACBA-5C0A444B2CAFQ35190149-7CC4BF56-6822-40DC-9B2D-D13C817CB6FFQ35261143-4DC63DD6-246B-42F5-979B-CFF160E330B5Q35529832-1B3CF92E-B33A-4139-B2E2-FD9DC9C6B89DQ35697443-1E614B42-3B2B-453A-A131-54BAD4EE1B7EQ35750016-1EEB8A9A-A29D-4F29-B1D2-ACAA84307244Q35846845-51EB41E0-83C6-4BF0-B3F2-0B5E6F0DFA3F
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
In vivo activity of nuclease-resistant siRNAs
@ast
In vivo activity of nuclease-resistant siRNAs
@en
In vivo activity of nuclease-resistant siRNAs
@nl
type
label
In vivo activity of nuclease-resistant siRNAs
@ast
In vivo activity of nuclease-resistant siRNAs
@en
In vivo activity of nuclease-resistant siRNAs
@nl
prefLabel
In vivo activity of nuclease-resistant siRNAs
@ast
In vivo activity of nuclease-resistant siRNAs
@en
In vivo activity of nuclease-resistant siRNAs
@nl
P2093
P2860
P356
P1433
P1476
In vivo activity of nuclease-resistant siRNAs
@en
P2093
Alice K Tanner
Anton P McCaffrey
Bruce A Sullenger
Juliana M Layzer
Mark A Kay
P2860
P304
P356
10.1261/RNA.5239604
P407
P577
2004-05-01T00:00:00Z